Edwards Lifesciences Corp
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, the company delivers life-changing innovations. It specializes in tissue heart valves and transcatheter technologies for the treatment of structural heart disease, with manufacturing facilities in Irvine, California, and other locations worldwide. The company is publicly traded on the NYSE under the ticker EW.
- 🔗 Edwards Lifesciences Corp
- 🔗 Edwards Lifesciences - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Edwards Lifesciences
- 🔗 Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equity | Edwards Lifesciences
- 🔗 Edwards Lifesciences Corp (EW) Stock Price & News - Google Finance
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Public company (NYSE: EW) focused on structural heart innovations since 1958.
- Completed $5,039,313 Rule 144 private placement with undisclosed investors.
- Maintains global manufacturing and a patient-focused culture serving over 100 countries.
- Has executed multiple Post-IPO Equity rounds including in 2000 and 2018.
Ask StreetZero about Edwards Lifesciences Corp
Put our AI to work on this deal.
Similar companies
Other Public Equity (NYSE) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account